INTRODUCTION {#s1}
============

Epilepsy occurs at a frequency of four to eight individuals per 1000 in the United States ([@MCS004135THOC30]; [@MCS004135THOC26]). Overall health-care costs for patients with epilepsy are proportional to the number of epileptic episodes with a threefold higher cost in patients with one or more seizures per week compared to individuals with less than one seizure per year ([@MCS004135THOC26]). Our knowledge of the various causes of epilepsy is still mostly unknown with approximately six out of 10 patients with unknown etiology ([@MCS004135THOC27]; [@MCS004135THOC28]). Frequently, there is a diagnostic odyssey undertaken to find the etiology including neurodiagnostics, neuroimaging, and metabolic and genetic testing.

With the advent of clinical genomic testing 10 years ago, physicians were empowered to progress from sequencing single genes in serial to sequencing hundreds to thousands of genes in parallel ([@MCS004135THOC19]). Indeed, genomic tests are not single tests but rather an aggregate of millions of tests comprised of individual nucleotide positions. The quick adoption of clinical genomic testing was accomplished because defects in many different genes result in the same clinical presentation; similarly, a single defective gene can exhibit many different phenotypes ([@MCS004135THOC49]). The prior paradigm of sequentially testing individual genes has a low diagnostic yield and infrequently provides a genetic explanation for a clinical diagnosis. Single-gene testing is a time-consuming and expensive process that is no longer practical in the evaluation of patients with epilepsy ([@MCS004135THOC75]). The capability to rapidly investigate multiple genes in parallel has solved diagnostic odysseys for many patients and families ([@MCS004135THOC46]). Still, it is unclear to most clinicians when to order genomic testing. The most recent guideline endorsed by the International League Against Epilepsy was published in 2010 and concludes, "... because the field is moving rapidly, with new information emerging practically every day, we present a framework for considering the clinical utility of genetic testing that can be applied to many different syndromes and clinical contexts. Given the current state of knowledge, genetic testing has high clinical utility in few clinical contexts, but in some of these it carries implications for daily clinical practice" ([@MCS004135THOC52]).

In this review, we will discuss the most commonly used genomic tests in clinical practice as it relates to epilepsy. We will also discuss the limitations to and pitfalls of genomic testing. Finally, we will discuss the potential cost-effectiveness of integrating genomic testing into routine clinical practice and present an operational approach for utilizing genomic testing.

TYPES OF GENOMIC TESTING {#s2}
========================

Microarray {#s2a}
----------

Since the early 2000s, chromosomal microarray analysis (CMA) has been available for genome-wide analysis. CMA techniques use nucleic acid probes to detect copy-number changes (gains and deletions) across the genome. When these copy-number changes occur in regions with genes, the loss or gain in gene function may be predicted. In one pediatric epilepsy study, 226 pediatric patients with first-time epilepsy were examined by CMA ([@MCS004135THOC74]). A clinically relevant copy-number variant was detected in 11% of patients (*n* = 24). The variants detected had a wide range in size from 88 kb to 21.1 Mbp. In another pediatric epilepsy study, 805 patients underwent CMA explaining 5% of cases (*n* = 40); the variants in this study ranged in size from 18 kb to 142 Mbp ([@MCS004135THOC51]). In one of the largest studies (*n* = 1255) of patients with epilepsy, 10.9% of patients had a pathogenic variant, and an additional 1.7% of patients had a copy-number variant that was deemed to be possibly pathogenic ([@MCS004135THOC10]). With a diagnostic yield of 5%--13%, CMA is a useful and sometimes critical test in the genetic diagnosis of epilepsy.

The copy-number information from microarrays can now be derived from some genomic DNA sequencing tests; thus, a single DNA test can identify both single-nucleotide variants and larger deletions of exons or whole genes. In a large study of 2603 patients with heterogeneous clinical presentations, reanalysis of exome data for copy-number variations identified a variant relevant to the patient\'s phenotype in 4.7% (*n* = 123) of cases; the variant sizes ranged from 727 bp to 15.3 Mbp. In a recent study focused on epilepsy, 168 families with epilepsy with negative test results from exome sequencing were reanalyzed using software designed to detect copy-number variation ([@MCS004135THOC72]). The exome data from these families was reanalyzed using software designed to detect copy-number variation. Pathogenic copy-number variants were detected in 10.7% of patients examined (*n* = 18). Compared to traditional CMA, the exome-derived data yielded a much wider range in size from 260 bp to 45.7 Mbp. This study suggests that existing patient data may have expanded utility with the development of new software algorithms. Genome-wide copy-number variation by CMA is still cost-effective to use for clinical diagnosis; however, in the near future, clinical laboratories will likely perform a single next-generation sequencing (NGS) test that assesses both single-nucleotide variation and copy-number variation.

Gene Panel {#s2b}
----------

In children with epilepsy of early onset or without specific dysmorphic features, targeted NGS panels are the most cost-effective initial test after electroencephalogram and neuroimaging. Diagnostic yield is variable depending on the population sampled. In one of the largest surveys of diagnostic yield, a summary of the clinical experience of a reference lab (GeneDx) examined the diagnostic yield of 8565 patients tested by gene panel (17, 18, 50, 53, and 70 genes in each panel) and exon-level microarray (December 2011 to December 2015) ([@MCS004135THOC38]). Overall, a 15.4% diagnostic yield was achieved in this heterogeneous population (average age, 5 yr 8 mo; range, 1 wk to 47 yr). The study not only identified the most commonly observed genes (*MECP2, KCNQ2, SCN1A, SCN2A, STXBP1, and PRRT2*), but also identified some genes that were only impacted by de novo variants (*CDKL5, STXBP1, SCN8A, GABRA1, and FOXG1*).

Studies on more defined populations have shown higher diagnostic yield from genomic testing. In a study of 74 pediatric patients with intractable early-onset epilepsy, a NGS panel of 172 genes demonstrated a 37.8% diagnostic yield ([@MCS004135THOC61]). The patients in this study had a 7.5 mo mean age of epilepsy; the majority of patients (85.1%) had epilepsy onset within the first year of life. The 37.8% diagnostic yield (*n* = 28) was attributed to 17 different genes, with the most frequently affected gene implicated in three cases (*STXBP1*). A separate study using a 46-gene NGS panel testing 216 patients with epilepsies ranging from neonatal seizures to epileptic encephalopathies ([@MCS004135THOC45]). A disease-causing variant was identified in 23% (*n* = 49) of patients. The cohort consisted of both pediatric and adult patients with 23% of \>18 yr of age. Of the 46 genes tested, 19 had disease-causing variants. Additionally, genes with disease-causing variants were sometimes implicated in more than one patient. The most frequently implicated gene was *SCN1A* (*n* = 12). The other genes that were implicated in more than one patient were *CDKL5* (*n* = 4), *GABRA1* (*n* = 2), *GABRB3* (*n* = 2), *KCNQ2* (*n* = 4), *SCN2A* (*n* = 6), *SCN8A* (*n* = 3), *SLC2A1* (*n* = 3), and *STXBP1* (*n* = 4). Nine additional genes were each implicated only once each. Neonatal-onset epilepsies (57%) followed by epileptic encephalopathies (32%) were most frequently diagnostic. Interestingly, in this study only 3% of cases reported had a variant of uncertain significance (VUS), whereas other studies have identified a VUS in \>30% of cases ([@MCS004135THOC38]; [@MCS004135THOC66]). This large difference in VUS detection rate probably can be attributed to differences in variant interpretation criteria; the use of recently published standardized interpretation guidelines ([@MCS004135THOC59]) shows a high rate of VUS detection in epilepsy panel studies ([@MCS004135THOC66]).

Exome {#s2c}
-----

In theory, exome studies are comprehensive tests that examine all DNA variants that encode protein. However, in the context of epilepsy, exome studies have overlapping diagnostic yield with gene panels ([@MCS004135THOC75]). A more recent exome study of epileptic encephalopathies identified de novo variants in 59% of patients ([@MCS004135THOC31]). Patients may have unique disease-causing variants that are not present in other family members. In theory, exome testing provides an unbiased approach for investigating rare genetic etiologies. In practice, when selecting clinical exome studies, the limited increase in diagnostic yield over gene panels should be recognized.

A large clinical exome study for patients with epilepsy examined 1131 patients: 314 had seizures and 817 were without seizures ([@MCS004135THOC29]). Both adult and pediatric patients were participants with the majority of patients examined by trio (proband plus biologic parents) analysis (80.9%). The remainder were a combination of proband only or proband plus one first-degree relative. The diagnostic yield of clinical exome was 33.4% for epilepsy patients (105 of 314). In comparison, the nonepilepsy group had a diagnostic yield of 25.9% (212 of 817). A total of 93 genes were implicated: 21 were found in two or more patients; six genes were seen in three or more patients (*KCNQ2, MECP2, FOXG1, IQSEC2, KMT2A, and STXBP1*). Of the patients tested, 80% previously had negative testing by microarray or targeted gene panels. This study was by a reference laboratory, and the authors recognized that the findings in the patients referred to their laboratory may not be generalizable to all patients with epilepsy.

Another approach to exome sequencing is to analytically sequence all coding genes, but only examine and interpret a subset of genes that were related to the patient\'s epilepsy type ([@MCS004135THOC56]). In 40 consecutive pediatric and adult patients with focal epilepsy, 64 epilepsy-associated genes were analyzed. In this study 12.5% (5 of 40 patients) had a disease-associated variant; one patient each for a defect in *SCN1A, DEPDC5, PCDH19, GABRG2,* or *NPRL2*. The median age of seizure onset of patients with an identified variant was 18 mo (range 8 mo to 18 yr) versus 18 yr (range 18 mo to 70 yr) for patients without an identified variant. This study identified a correlation between age of epilepsy onset and the diagnostic yield; patients with onset of epilepsy before the age of 2 yr were more likely to have positive genetic findings.

Building on this concept, a prospective study has focused on the use of genetic testing in children with epilepsy onset at \<3 yr of age ([@MCS004135THOC7]). This multi-institutional study enrolled 775 patients with a median age of onset of 7.5 mo. A subset of 327 patients underwent genetic testing, and 40.4% received a genetic diagnosis. The study included karyotype, microarrays, epilepsy gene panels, exomes, and mitochondrial panels and other tests. The highest yield test in this study was karyotype (26 of 59, 44.1%), followed by exome (11 of 33, 33.3%), 31 of 114 epilepsy panels (27.2%), mitochondrial panels (4 of 20, 20%), and microarrays 32 of 188 (17%). The authors concluded that genetic investigation should be part of the initial evaluation of early-onset epilepsy, and testing should be individualized based on the clinical presentation.

A parallel comparison of exome versus conventional genetic testing in 150 pediatric patients with complex neurologic disorders used both conventional diagnostic workup (imaging, biopsies, lumbar punctures, and sequential gene-specific testing) and exome sequencing (trio) ([@MCS004135THOC73]). The majority of patients (*n* = 143) did not have a family history of neurologic disorders. The most frequent clinical findings in the patients were intellectual disability (*n* = 78), movement disorders (*n* = 20), and neuromuscular disease (*n* = 8). The patients examined by exome sequencing alone had a higher diagnostic yield of 29.3% compared to the conventional diagnostic workup\'s yield of 7.3%. The conventional diagnostic workup with sequential single gene sequencing had an average of 4.6 genetic tests performed before reaching a diagnosis. The study also examined diagnostic concordance between exome and conventional workup. Eight patients reached the same diagnosis by either method. Thirty-six patients only had a diagnosis by exome, and three patients only had their diagnosis through conventional diagnostic workup with sequential gene testing. The three patients with a genetic diagnosis missed by exome included a patient with 9-bp duplication event, a repeat expansion in *FMR1*, and a mosaic 27-Mbp duplication of Chromosome 7. This study is unique because it examines the role of exome testing in comparison to conventional diagnostic modalities. Future studies on exome or other advanced genomic technologies should utilize this design of direct comparison with conventional diagnostic modalities.

TECHNICAL LIMITATIONS AND PITFALLS {#s3}
==================================

An important concept to consider when selecting any genomic test is that there is only a subset of genes that is clinically useful to analyze. Of the greater than 18,000 genes that encode protein, less than 6000 currently have specific associations with human disease. Although both coding and noncoding variants are identified, the clinical analysis is limited to variants near or in genes with known association with human disease. To put this into perspective, of the three billion bases examined in whole-genome testing, \<1% of the data is currently useful for clinical diagnosis. Indeed, the technology for sequencing DNA has advanced to the point that the ability to test DNA outpaces the ability to ability to deliver affordable and clinically meaningful interpretations that are relevant to the patient\'s care.

Other limitations of genomic tests include incidental findings, nonpaternity, and analytical failures. Genomic tests may uncover incidental (secondary) findings of significant consequence to the future health and unrelated to the patient\'s current health ([@MCS004135THOC24]; [@MCS004135THOC35]). Incidental findings are estimated to be in 1%--3% of the U.S. population and include adult-onset diseases such as cancer, cardiac abnormalities, or neurodegenerative disease ([@MCS004135THOC17]). In addition to genetic findings unrelated to the patient\'s current health, genetic tests may reveal nonpaternity. Nonpaternity varies widely depending in studies with a median rate of 3.7% (range 0.8% to 30%) ([@MCS004135THOC6]). Limitations of incidental findings and nonpaternity can be mitigated by careful pretest counseling of the patient and/or family.

Analytical inconsistencies or failures are a sign of the relative newness of the technology. The quality metrics for standardization of testing is still in flux. Specifically, for epilepsy testing, the content (genes examined) has been in constant evolution. New genetic discoveries may increase the number of relevant genes to be tested. Thus, there may be variation in the exact genes examined by different laboratories. Alternatively, a laboratory may provide testing by using an exome kit; however, laboratories may analyze all genes in the exome or only examine a small subset of genes that they deem to be clinically relevant.

Analytical quality metrics are also evolving in terms of how "deeply" genomic tests sequence a target. Each nucleotide position needs 40 reads per nucleotide position (40×) to achieve a 95% confidence of a heterozygous change ([@MCS004135THOC41], [@MCS004135THOC42]). The commonly used target for minimum reads of data is 20 (20×); however, this is predicted to miss 5%--15% of heterozygous variants, which could be a critical error in rare disease detection ([@MCS004135THOC41]). In studies of both exome ([@MCS004135THOC53]) and whole-genome ([@MCS004135THOC15]) sequencing, small inadequacies in coding nucleotide coverage can lead to clinically significant deficiencies in analysis of important genes.

Another quality consideration is confirmation by Sanger sequencing. The quality of NGS is improving and some have suggested that Sanger confirmation is no longer necessary ([@MCS004135THOC5]). However, other studies have shown that although NGS quality is quite high (\>90% of variants identified), there are specific analytical scenarios in which Sanger confirmation is necessary ([@MCS004135THOC69]; [@MCS004135THOC4]). From the perspective of clinical providers and patients, there should be a preference for laboratories that either perform Sanger confirmation of all clinically important variants or otherwise have established criteria for when Sanger confirmation is necessary.

A future consideration for genomic testing is the need for longitudinal reinterpretations. For example, a patient presenting with intractable epilepsy at 2 yr of age may have a genomic test performed and VUSs with or without clinical significance may be identified. Any variants that are identified are interpreted at the time of the testing, but these variants can also be reinterpreted with the passage of time and the development of the medical literature. Periodic reanalysis of existing genetic data is not performed by all clinical laboratories. However, studies have shown that genetic diagnoses may significantly change over time ([@MCS004135THOC11]; [@MCS004135THOC32]; [@MCS004135THOC40]; [@MCS004135THOC66]). The types of diagnostic changes include not only upgrades from uncertain diagnosis to disease-causative diagnosis, but also can include downgrades from pathogenic diagnoses to benign findings. The physicians who use genomic tests must communicate with their patients that the interpretation of genetic variants may change with advances in medical knowledge. Furthermore, as pediatric patients reach majority status and seek information on the risk of future-onset diseases (e.g., neurodegenerative, cancer), then an exome data set should be made available for further reanalysis for adult-onset disorders. Clinical care providers who order genomic testing on their patients should be familiar with a basic checklist of quality considerations for clinical genomic laboratories ([Table 1](#MCS004135THOTB1){ref-type="table"}).

###### 

Quality checklist in clinical laboratory and test selection

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Accreditation**---Quality programs (accreditation) and certifications for the laboratory. In the United States, CLIA is the most basic type of clinical laboratory certification. The College of American Pathologists (CAP) provides specific accreditation requirements and on-site inspections for genomic laboratories. Some states such as New York have specific requirements for genomic testing.
  **Genes tested**---For a panel, the exact genes tested should be provided. For exome, the laboratory should be able to provide information on which genes are completely tested (e.g., 100% of coding nucleotides at ≥20× at all nucleotide positions) or partially tested.
  **Sanger confirmation**---Sanger confirmation of genomic test results. The laboratory should provide criteria for when Sanger confirmation is performed.
  **Variant reinterpretation**---How does the laboratory update providers and patients of changes in the classification of clinical significance of variants?
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TREATMENT IMPLICATIONS {#s4}
======================

Although genomic testing is predominantly diagnostic, there are treatment implications in some cases. In a retrospective review of 50 patients with exome testing, 48% had a genetic diagnosis; the majority of management changes from those diagnoses were prognostic or informative for family planning ([@MCS004135THOC48]). However, there were five genes in patients that involved medication changes: *CACNA1A* (acetazolamide); *NSD1* (discontinued mitochondrial cocktail); *SCN1A* (avoid carbamazepine, lamotrigine, or vigabatrin); *SLC13A5* (citrate transport defect; acetazolamide improved some symptoms); and *WDR45* (associated sleep concerns; started clonidine). In another series, a patient was discovered to have compound heterozygosity of pathogenic variants in *PNPO* (pyridoxamine 5-prime-phosphate oxidase) and was placed on oral vitamin therapy ([@MCS004135THOC23]). Importantly, although the patient was seizure-free on a combination of pyridoxal 5-phosphate and valproate, his preexisting severe developmental delays and visual deficits did not improve. Beyond vitamin-responsive epilepsies, NGS panels are helpful in identifying other diagnoses that have emerging evidence for precision medicine including GLUT-1 spectrum disorders, certain sodium and potassium channelopathies, and other rare inborn errors of metabolism (e.g., cerebral creatine deficiency syndromes) ([Table 2](#MCS004135THOTB2){ref-type="table"}; [@MCS004135THOC14]).

###### 

Genes and syndromes with therapeutic implications

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene        Syndrome(s)                                                                                                                   Therapeutic implication
  ----------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *ALDH7A1*   Epilepsy, pyridoxine-dependent                                                                                                Pyridoxine ([@MCS004135THOC76])

  *CACNA1A*   Calcium channelopathy associated with ataxia                                                                                  Acetazolamide ([@MCS004135THOC67]; [@MCS004135THOC48])

  *CHRNA2*    Autosomal dominant nocturnal frontal lobe epilepsy                                                                            Nicotine ([@MCS004135THOC22])

  *CHRNA4*    Autosomal dominant nocturnal frontal lobe epilepsy                                                                            Nicotine ([@MCS004135THOC55]; [@MCS004135THOC22]; [@MCS004135THOC50])

  *CHRNB2*    Epilepsy, nocturnal frontal lobe, 3                                                                                           Nicotine ([@MCS004135THOC77]; [@MCS004135THOC65])

  *EPM2A*     Epilepsy, progressive myoclonic 2A (Lafora)                                                                                   Avoid sodium channel blockers (lamotrigine and phenytoin) ([@MCS004135THOC34])

  *GRIN2A*    Epileptic encephalopathy, epileptic-aphasia syndrome (Landau--Kleffner syndrome, lectrical status epilepticus during sleep)   Memantine ([@MCS004135THOC57])

  *KCNQ2*     Epileptic encephalopathy, early infantile, 7                                                                                  Carbamazepine, oxcarbazepine, phenytoin ([@MCS004135THOC58]; [@MCS004135THOC63])

  *KCNQ3*     Seizures, benign neonatal, 2                                                                                                  Phenobarbital, carbamazepine ([@MCS004135THOC63])

  *KCNT1*     Epilepsy, nocturnal frontal lobe, 5\                                                                                          Quinidine^a^ ([@MCS004135THOC43])
              Epileptic encephalopathy, early infantile, 14                                                                                 

  *PCDH19*    Epileptic encephalopathy, early infantile, 9                                                                                  Ganaxolone ([@MCS004135THOC20]); stiripentol ([@MCS004135THOC71])

  *PNPO*      Pyridoxamine 5′-phosphate oxidase deficiency                                                                                  Pyridoxal-5-phosphate (vitamin B~6~) ([@MCS004135THOC44]; [@MCS004135THOC25])

  *POLG*      Mitochondrial DNA depletion syndromes 4A, 4B\                                                                                 Avoid sodium valproate ([@MCS004135THOC68])
              Mitochondrial recessive ataxia syndrome\                                                                                      
              Progressive external opthalmoplegias                                                                                          

  *PRRT2*     Convulsions, familial infantile, with paroxysmal choreoathetosis\                                                             Carbamazepine ([@MCS004135THOC37]; [@MCS004135THOC13])
              Episodic kinesigenic dyskinesia 1\                                                                                            
              Seizures, benign familial infantile, 2                                                                                        

  *SCN1A*     Epilepsy, generalized, with febrile seizure plus, type 2\                                                                     Bromide ([@MCS004135THOC39]; [@MCS004135THOC64]); stiripentol ([@MCS004135THOC2]); avoid sodium channel blockers (lamotrigine and phenytoin) ([@MCS004135THOC48]; [@MCS004135THOC64])
              Epileptic encephalopathy, early infantile, 6 (Dravet)\                                                                        
              Febrile seizures, familial, 3A\                                                                                               
              Migraine, familial hemiplegic, 3                                                                                              

  *SCN2A*     Epileptic encephalopathy, early infantile, 11\                                                                                High-dose phenytoin ([@MCS004135THOC16]; [@MCS004135THOC21])
              Seizures, benign familial infantile, 3                                                                                        

  *SCN8A*     Epileptic encephalopathy, early infantile, 13\                                                                                High-dose phenytoin ([@MCS004135THOC3]; [@MCS004135THOC8])
              Seizures, benign familial infantile, 5                                                                                        

  *SLC13A5*   Epileptic encephalopathy, early infantile, 25                                                                                 Acetazolamide ([@MCS004135THOC48]); stiripentol ([@MCS004135THOC1])

  *SLC2A1*    GLUT1 deficiency syndrome                                                                                                     Ketogenic diet, triheptanoin ([@MCS004135THOC54]; [@MCS004135THOC36])

  *TSC1*      Tuberous sclerosis-1                                                                                                          Vigabatrin, everolimus ([@MCS004135THOC12])

  *TSC2*      Tuberous sclerosis-2                                                                                                          Vigabatrin, everolimus ([@MCS004135THOC12])
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adapted from [@MCS004135THOC14].

^a^Quinidine may be ineffective ([@MCS004135THOC47]).

COST-EFFECTIVENESS {#s5}
==================

In Canada, a cost study model, CAUSES (clinical assessment of the utility of sequencing and evaluation for service) examined service delivery models of singleton (proband only) exome and trio exome sequencing ([@MCS004135THOC18]). The goal of the model is to provide expert consultation in suspected monogenic disorders in British Columbia in efforts to define clinical utility of exome and genome sequencing. The clinical delivery service model in CAUSES includes clinical consultation with a committee of genetics specialists, test facilitation in a contract research laboratory, and analysis of the research laboratory data by the CAUSES team. Any clinically significant variants were confirmed by Sanger sequencing in a hospital-based clinical laboratory and subsequently reported in the medical record and discussed with families. The CAUSES study included analysis of 500 families. In their model simulation using data from their CAUSES delivery of care, the cost assessment (including all clinical services) was \$6437 versus \$2576 for trio and singleton, respectively. Importantly, this study modeled a cost per positive diagnosis and estimated that the cost per positive diagnosis was \$19,340 and \$10,700 for trio and singleton, respectively. This is not the first cost analysis study of exome testing, but it is one of the more comprehensive studies that takes into account not only the cost of the test, but also the cost of each of the clinical components that associated with the test such as genetic counseling, travel, and other costs. The authors report that only 4% of the patients in their study had incidental findings; however, the downstream cost of incidental findings reported to patients was not calculated or modeled.

In Australia, [@MCS004135THOC70] examined the utility of singleton exome sequencing in pediatric patients with suspected monogenic disorder who had not had previous genetic testing. Forty-four children were enrolled in this prospective study and the diagnostic yield within this population was 52%. In their exome analysis only a subset of 3203 genes were examined. A clinical history of epilepsy was not a specific focus of their study, but many patients had a CNS phenotype characterized by intellectual disability. Overall, the authors projected the total health costs (including medical consultations, neurophysiological testing, diagnostic testing, travel, etc.) of these 44 patients to be \>\$430,000 (\$9772 per patient). In terms of diagnostic testing, the authors proposed four different diagnostic models: (1) standard management without exome; (2) standard management with exome; (3) exome at initial tertiary care appointment; and (4) exome at initial genetics appointment. Within their model, the lowest cost per diagnosis cost was found with exome sequencing at initial tertiary care management (\$7526 per diagnosis) followed by exome at first genetics visit (\$10,225 per diagnosis). Importantly, there was no predicted savings by performing exome after a standard diagnostic workup, suggesting exome sequencing may be a reasonable first-line test in suspected pediatric monogenic disorders.

Cost-effectiveness of genomic testing has been examined specifically for patients with severe epilepsies of infancy ([@MCS004135THOC33]). An incremental cost-effectiveness ratio was examined for patients with epilepsy diagnosed from 2011 to 2013. Patients were included when meeting the criteria of seizure onset before 18 mo of age, frequent seizures, epileptiform EEG, and failure of two or more antiepileptic drugs. As part of routine care, genetic testing was only performed when MRI and EEG were negative. The genetic testing included gene sequencing panels (39 to 65 genes), chromosomal analysis, and exome and whole-genome sequencing. The particular exome analysis in this study was exome sequencing with analysis and interpretation limited to 341 genes known to be associated with infantile-onset epilepsy. The overall diagnostic yield for genetic testing was 54% (62 of 114). Cost-effectiveness was then modeled using only the exome data to calculate the cost per diagnosis if the exome were performed earlier or later in the patient\'s care. The baseline model used no exome testing and had a diagnostic yield of 45% with a total cost of \$661,103 and an average cost per diagnosis \$16,951. In contrast when exome was used early in the patient\'s care (after MRI, microarray, routine blood, and urine metabolic tests), a diagnostic yield of 53% was achieved with overall lower cost---\$445,597 total cost and an average cost per diagnosis of \$9904. *The least cost-effective model was using exome as the last diagnostic modality*---\$738,136 total cost and an average cost per diagnosis of \$15,378. The investigators concluded that exome testing is clinically important and cost-effective in evaluation of early-onset intractable epilepsy. Other studies have noted cost savings ranging from \$2000 to \$7000 per diagnosis when exome sequencing is considered early in the diagnostic pathway ([@MCS004135THOC60]; [@MCS004135THOC73]). A recent meta-analysis identified the diagnostic yield and cost-effectiveness of CMA, gene panels, and exome for patients with epilepsy ([@MCS004135THOC62]). In this study, exome had the highest diagnostic yield of 32% (range 22%--44%), followed by gene panels (23%; 18%--29%), and CMA (8%; 6%--12%). Based on these diagnostic yields, the most cost-effective test was gene panel testing with an incremental cost-effectiveness ratio of \$15,848 per diagnosis, followed by exome with \$34,500 per diagnosis. The authors identified the most cost-effective strategy as a gene panel, followed by CMA, then exome. The meta-analysis did not support CMA as a first-tier diagnostic test for patients with epilepsy.

There is inconsistent insurance coverage of genetic testing in the United States. Indeed, the evidence used by insurers in the United States for coverage of genetic testing is different than evidence used for other medical tests such as radiology and drug approval ([@MCS004135THOC9]). In a systematic study, five insurance payers were examined for a total of 55 relevant coverage policies relevant to 313 gene panels. Clinical guidelines were cited in 84% of policies (range 73%--100%). Cost-effectiveness and budget impact studies were rarely cited by payers (5% of policies with a range of 0%--7%). Individual clinical studies were cited in 69% of policies (range 50%--87%). The reason for inconsistent coverage is multifactorial, including evolving techniques and technologies, lack of long-term clinical information on rare genetic disorders, and difficulty defining the clinical validity and utility of gene panel tests. The inconsistent financial coverage of genomic testing for patients with epilepsy remains a major obstacle to clinical implementation in the United States.

CONCLUSIONS {#s6}
===========

Genomic testing in epilepsy is evolving diagnostically and there are emerging therapeutic considerations for a number of genetic epilepsy syndromes. However, the literature supports that a thorough clinical assessment is needed prior to evaluating a patient by a genomic test. Previous studies have confirmed that diagnostic yields in certain epilepsy populations lead to high diagnostic rates and are cost-effective in comparison to conventional diagnostic modalities and prior methods of serial sequencing of individual genes.

In the current era of clinical medicine, which is characterized by financial pressures and cost sensitivity, clinical practitioners need to be judicious in cost of their patient management. Prior authorization has become a routine step in the process for obtaining genomic testing for patients. From the perspective of cost mitigation, our clinical practice has implemented a clinical pathway for genomic testing in pediatric epilepsy ([Fig. 1](#MCS004135THOF1){ref-type="fig"}). Moreover, there is mounting evidence that genomic testing in intractable epilepsy with childhood onset may lead to precision therapies and is becoming standard practice at most tertiary care institutions. Indeed, we stipulate that these genetic testing methods will lead to more streamlined diagnostic algorithm and ultimately provide life-changing precision medicine to patients with epilepsy.

![Clinical pathway for genomic evaluation of pediatric epilepsy. A clinical pathway for genomic management of pediatric patients with epilepsy begins with a clinical diagnosis of epilepsy by a neurologist. This is followed by routine EEG and brain MRI. If the patient has a diagnostic MRI and/or EEG, the patient proceeds to targeted testing and individualized ASM followed by subspecialty referral for further management by epileptologists and/or genetic specialists. If the MRI and/or EEG are not diagnostic, the patient is started on an empiric course of ASM. If the patient has either two failures of empiric therapy or one failure of empiric therapy and an additional risk factor, then the patient has genomic epilepsy testing performed (gene panel vs. exome \[proband-only or trio\]). After genomic testing, the patient is then referred to subspecialty consultation with an epileptologist and/or genetic specialist. \*Standard of care testing for children with developmental delay includes CMA and fragile X (if male). (ASD) Autism spectrum disorder, (ASM) antiseizure medication, (CMA) chromosomal microarray, (EEG) electroencephalogram, (ID) intellectual disability, (MRI) magnetic resonance imaging.](MCS004135Tho_F1){#MCS004135THOF1}
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